PMID- 17220902
OWN - NLM
STAT- MEDLINE
DCOM- 20070327
LR  - 20131121
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 39
IP  - 4
DP  - 2007 Feb
TI  - Total body irradiation and granulocyte colony-stimulating factor-combined 
      high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem 
      cell transplantation for advanced myelodysplastic syndrome: a single-institute 
      experience.
PG  - 217-21
AB  - In this study, we retrospectively evaluated the efficacy and safety of total body 
      irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined 
      high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem 
      cell transplantation (HSCT) in patients with advanced myelodysplastic syndrome 
      (MDS). We evaluated 22 patients with advanced MDS, including refractory anemia 
      with excess blasts (RAEB; n=10), RAEB in transformation (n=2), acute myelogenous 
      leukemia transformed from MDS (n=6) and chronic myelomonocytic leukemia (n=4). 
      The conditioning regimen consisted of 12 Gy of TBI and high-dose cytarabine (3 
      g/m(2)) every 12 h for 4 days, and the cytarabine was combined with continuous 
      administration of G-CSF. The stem cell sources were bone marrow or peripheral 
      blood stem cells from human leukocyte antigen (HLA)-identical siblings (n=12) and 
      bone marrow from HLA serologically matched unrelated donors (n=10). Three 
      patients experienced disease relapse, two of whom died of disease progression. Of 
      22 patients, 16 are currently alive and disease-free. The 5-year estimated 
      overall survival, disease-free survival, relapse and non-relapse mortality rates 
      are 76.7, 72.2, 16.6 and 14.1%, respectively. These results suggest that 
      G-CSF-combined high-dose cytarabine could be a promising component of the 
      conditioning regimen of allogeneic HSCT for advanced MDS, providing a low 
      incidence of both relapse and treatment-related mortality.
FAU - Mori, T
AU  - Mori T
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan. tmori@sc.itc.keio.ac.jp
FAU - Aisa, Y
AU  - Aisa Y
FAU - Yokoyama, A
AU  - Yokoyama A
FAU - Nakazato, T
AU  - Nakazato T
FAU - Yamazaki, R
AU  - Yamazaki R
FAU - Shimizu, T
AU  - Shimizu T
FAU - Mihara, A
AU  - Mihara A
FAU - Kato, J
AU  - Kato J
FAU - Watanabe, R
AU  - Watanabe R
FAU - Takayama, N
AU  - Takayama N
FAU - Ikeda, Y
AU  - Ikeda Y
FAU - Okamoto, S
AU  - Okamoto S
LA  - eng
PT  - Journal Article
DEP - 20070115
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Myeloablative Agonists)
RN  - 04079A1RDZ (Cytarabine)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bone Marrow Transplantation
MH  - Cytarabine/*administration & dosage/adverse effects
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/*administration & dosage/adverse effects
MH  - Hematopoietic Stem Cell Transplantation/methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myeloablative Agonists/*adverse effects
MH  - Myelodysplastic Syndromes/*drug therapy
MH  - Retrospective Studies
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous/methods
MH  - *Whole-Body Irradiation/adverse effects
EDAT- 2007/01/16 09:00
MHDA- 2007/03/28 09:00
CRDT- 2007/01/16 09:00
PHST- 2007/01/16 09:00 [pubmed]
PHST- 2007/03/28 09:00 [medline]
PHST- 2007/01/16 09:00 [entrez]
AID - 1705578 [pii]
AID - 10.1038/sj.bmt.1705578 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2007 Feb;39(4):217-21. doi: 10.1038/sj.bmt.1705578. Epub 
      2007 Jan 15.